FDA puts Curis' leukemia trial on partial hold after patient death spurs review of muscle breakdown

Submitted by admin on April 4, 2022 - 10:35am

Source:

Fierce Biotech

News Tags:

Curis

FDA

clinical trials

patient deaths

emavusertib

acute myeloid leukemia

Headline:

FDA puts Curis' leukemia trial on partial hold after patient death spurs review of muscle breakdown

snippet:

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers information about the death of a patient.

Search form

You are here

FDA puts Curis' leukemia trial on partial hold after patient death spurs review of muscle breakdown

FDA puts Curis' leukemia trial on partial hold after patient death spurs review of muscle breakdown